We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




MicroRNA Profiling Shows Promise as Diagnostic and Prognostic Tool for Bladder Cancer

By LabMedica International staff writers
Posted on 28 Aug 2013
Profiling of 15 microRNAs (miRNAs) from bladder tissue showed with 100% accuracy whether the cells were normal or malignant, while the determination of only two miRNAs could predict how well the patient would be able to defend against bladder cancer.

Bladder cancer is a common cancer in the Western world. More...
However, the current prognosticators such as tumor grade, stage, size, and multifocality do not accurately reflect the clinical outcome. In about three-quarters of bladder cancer patients the tumors are confined to the mucosa or submucosa (non-muscle invasive bladder cancer, NMIBC), whereas in the rest of the cases the cancers have already invaded nearby muscle (muscle-invasive bladder cancer, MIBC).

Investigators at University Hospital Charité (Berlin, Germany) turned to the profiling of microRNAs from bladder tissue as a better way to detect cancer and predict how it would likely grow and spread. MicroRNAs are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.

The investigators screened 723 miRNAs by microarray and selected a subset of 15 distinctively deregulated miRNAs for further validation by real-time quantitative RT-(q)PCR. Seven miRNAs were found to be up-regulated and eight miRNAs were found to be down-regulated in malignant bladder tissue samples compared to healthy tissue. Four miRNAs that had already been described in the literature (miR-141, miR-199a-3p, miR-205, and miR-214) were significantly differentially expressed between non-muscle-invasive and muscle-invasive bladder cancer.

When all 15 of the selected miRNAs were considered together, they correctly classified 100% of tissues as either normal or malignant, and two miRNAs (miR-141 and miR-205) significantly correlated with survival.

"These results underline the great potential of miRNAs to serve as diagnostic markers, as previously noted for other urological tumors," said senior author Dr. Klaus Jung, professor of urology at the University Hospital Charité. "These findings could be of clinical importance, but these results must be interpreted cautiously. However, previously published studies underline the possible prognostic potential of miRNAs to predict progression and disease-specific or overall survival in bladder cancer patients."

The study demonstrating the usefulness of miRNA profiling for diagnosis and prognosis of bladder cancer was published in the August 14, 2013, online edition of the Journal of Molecular Diagnostics.

Related Links:
University Hospital Charité




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
HPV Test
Allplex HPV28 Detection
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.